Intellia dosed first patient in NTLA-2002 Phase 2; Q1 net loss $103.1M, cash $1.2B

Intellia Therapeutics, Inc.

2023-Q1 EPS reported -$1.17 revenue$12,606,000

Dosed first patient in global Phase 2 study of NTLA-2002 for HAE; enrollment completion expected 2H 2023.
Plans to submit IND in mid-2023 for global pivotal trial of NTLA-2001 for ATTR-CM; study initiation expected by year-end 2023.
Cash, cash equivalents and marketable securities of $1.2B as of March 31, 2023; net loss $103.1M for Q1 2023.
R&D expenses decreased to $97.1M from $133.1M YoY, partially due to absence of Rewrite acquisition expense.
Collaboration revenue increased to $12.6M from $11.3M; G&A expenses rose to $27.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intellia Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

CAMBRIDGE, Mass., May 4, 2023 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.